Together, these results support the idea of plasma NfL levels as being a marker of neurodegeneration, but not specific for AD, and suggest plasma p-tau181 levels could be used for both the diagnosis of AD and the prediction of disease progression in memory clinic patients. This evidence concerns the gene OCA2 and Alzheimer disease.